Latest Syk Stories
SOUTH SAN FRANCISCO, Calif., June 16, 2011 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul R. Rodriguez, the company's president and chief operating officer, is scheduled to present a company overview at the Wells Fargo Securities 2011 Healthcare Conference in Boston, MA on Thursday, June 23rd at 9:30 a.m. ET. To access the live audio webcast of the company presentation or the subsequent archived recording, log on to www.rigel.com. Please connect to...
SOUTH SAN FRANCISCO, June 3, 2011 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at the Jefferies 2011 Global Healthcare Conference in New York City on Wednesday, June 8th at 2:30 pm ET. The presentation will be webcast live and can be accessed at www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live...
SOUTH SAN FRANCISCO, Calif., May 5, 2011 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Ryan Maynard, the company's chief financial officer, is scheduled to present a company overview at the Bank of America Merrill Lynch Health Care Conference in Las Vegas on Tuesday, May 10th at 10:00 a.m. PT. (Logo: http://photos.prnewswire.com/prnh/20030226/RIGLLOGO) The presentation will be webcast live and can be accessed at www.rigel.com. Please connect to Rigel's...
SAN FRANCISCO, Feb. 28, 2011 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at three investment conferences during the month of March. Details of each conference are as follows: Citi Global Health Care Conference Date: Wednesday, March 2nd at 1:30 p.m. ET Location: New York, NY Cowen and Company 31st Annual Health Care...
SOUTH SAN FRANCISCO, Calif., Feb. 9, 2011 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to participate at two investor conferences in New York City next week. Details of the events are as follows: Tuesday, February 15 at 9:00 a.m. ET 13th Annual BIO CEO & Investor Conference Panel Topic: "Rheumatoid Arthritis: the Real Joint Problem" Tuesday, February 15...
SAN FRANCISCO, Jan. 6, 2011 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at the JP Morgan Healthcare Conference in San Francisco, CA on Thursday, January 13th at 11:30 a.m. PST. (Logo: http://photos.prnewswire.com/prnh/20030226/RIGLLOGO) To access the live audio webcast or the subsequent archived recording, log on to www.rigel.com. Please connect...
SOUTH SAN FRANCISCO, Calif., Nov. 23, 2010 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at the 22nd Annual Piper Jaffray Health Care Conference in New York on Wednesday, December 1st at 3:00 p.m. EST. To access the live audio webcast or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's website several...
SOUTH SAN FRANCISCO, Calif., Oct. 28 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, chairman and chief executive officer, and Raul R. Rodriguez, president and chief operating officer of Rigel, will present at two separate investor conferences in November. Details of each conference are as follows: Oppenheimer 21st Annual Healthcare Conference New York, NY November 3, 1:35 p.m. EDT Speaker: Raul R. Rodriguez...
SOUTH SAN FRANCISCO, Calif., Sept. 29 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has earned $25 million from AstraZeneca for the fulfillment of two major milestones in the agreement the two companies have regarding the clinical development of fostamatinib (R788), a novel oral syk inhibitor. The first milestone is for initiation of the phase 3 clinical program with fostamatinib in patients with rheumatoid arthritis (RA) that was announced by...
SOUTH SAN FRANCISCO, Calif., July 28 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at BMO Capital Markets 10th Annual Focus on Healthcare Conference in New York City on Thursday, August 5th at 2:15 p.m. EDT. To access the live audio webcast or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's website...
